Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026GlobeNewsWire · 2 days ago
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal CancerGlobeNewsWire · Sep 29, 2026
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?Zacks Investment Research · Sep 17, 2026
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity StudyMarketBeat · Sep 15, 2026
Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'Benzinga · Sep 14, 2026
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of ObesityGlobeNewsWire · Sep 14, 2026Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$1.26 | -$1.81 | Miss |
| May 12, 2026 | -$1.26 | -$1.23 | Beat |
| Mar 9, 2026 | -$1.78 | -$1.25 | Beat |
| Nov 12, 2025 | -$1.80 | -$1.90 | Miss |
| Aug 5, 2025 | -$1.55 | -$1.44 | Beat |
| May 6, 2025 | -$1.26 | -$1.39 | Miss |